Adult diapers are disposable urinary incontinence products, one of the adult care products, and a disposable diaper mainly suitable for incontinent adults.
Most products are flaky and shorts type. Use adhesive sheets to connect into a pair of shorts. The adhesive sheet also has the function of adjusting the waist size so as to fit different fat and thin body shapes.
Generally, the structure of diapers is divided into three layers from the inside to the outside. The inner layer is close to the skin and made of non-woven fabric; the middle layer is water-absorbent fluff pulp, added with polymer water-absorbing agent; the outer layer is an impermeable breathable film. Adult Briefs,Depends Adult Diapers,Adult Diapers For Sale,Adult Disposable Diapers Shandong Kangshun Daily Products Co., Ltd , https://www.centurybenifit.com
Medical Network April 17th On April 13, the State Administration of Markets and Administration completed the administrative approval of the Merck's five-valent rotavirus vaccine in China, and is currently in the state of making drug certificates. The vaccine is still used by Zhifei Bio-agent to prevent children's rotavirus diarrhea. It is expected to be officially launched in China in the third quarter of this year. It is expected to bring about 500 million yuan in net profit per year to Zhifei.
It is understood that rotavirus is the main cause of diarrhea in infants and young children , and it is easy to cause death. According to the WHO survey, 5% of deaths among children under five in developing countries are caused by rotavirus diarrhea. According to the survey in China, the detection rate of rotavirus in children aged 6-23 months is more than 42%. Nearly 40,000 children die each year from rotavirus diarrhea, accounting for about 12% of the total number of deaths among children under 5 years old in China.
Rotavirus diarrhea is one of the "four children's diseases" in China. At present, the rotavirus vaccine listed in China is only the seedlings produced by Lanzhou Biological Products Research Institute Co., Ltd., according to the batch number of 4,484,800 doses issued in 2017, the winning price is 172 yuan / dose (the latest in Guizhou Province on March 14) The bid price is estimated. The domestic market is nearly 1 billion yuan, and the market potential is huge.
According to Zhifei Bio 2017 annual performance report, during the reporting period, the company achieved revenue of 1.343 billion yuan, an increase of 201.06%; net profit of 432 million yuan, an increase of 1229.25%.